Filing excerpt
On January 30, 2026, the Company completed the Transaction.
sec.gov/Archives/edgar/data/1110803/000111080326000014/ilmn-20260130.htmRead the full source
Illumina8-K: Acquisition completed
Illumina completes $350M cash acquisition of Standard BioTools' proteomics business
What happened
Illumina has acquired SomaLogic and other entities for $350M cash plus up to $75M in milestones, signaling a major strategic expansion into proteomics.
Source
Other signals in this filing (3)
- Capex increaseIllumina completes $350M cash acquisition of proteomics business from Standard BioToolsCapex increase
- Software implementationIllumina completes $350M acquisition, triggering massive systems and data integration project.Software implementation
- RestructuringIllumina's $350M acquisition of SomaLogic and Sengenics triggers major organizational restructuring.Restructuring
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Acquisition completed
What this signalsIntegration work after a deal often opens needs for new systems and services.
- Form
- 8-K
- Filed
- Jan 30, 2026
More from Illumina
- PatentsIllumina was granted a patent for substrates supporting sample quantification.Patents
- RedditA user experiencing periodic 10 bp peaks in RNA-seq data from an Illumina NovaSeq X Plus was informed by a self-identified Illumina employee that this pattern is a known artifact of...Reddit
- Web trafficillumina.com shows sustained decline with 3 consecutive months of decreases, down 24% overall to 635K.Web traffic
- GlassdoorLack of career growth and slow promotions reported by employeesGlassdoor
- Website changesIllumina expanded the catalog’s cross-selling and bundled-product presentation with additional “Frequently purchased together” and “View all bundles” calls to action.Website changes
- 8-KIllumina raises $300M in new debt to refinance existing notes maturing in September 2026.8-K
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordNumbers
- Dollar figure
- $350M (Cash purchase price for Standard BioTools' proteomics business)
Details
- CIK
- 1110803
- Accession number
- 0001110803-26-000014
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Active integration needs
- Signal category
- Strategic
Topics and mentions
Technologies
- proteomics
Regions named
- Singapore
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Neutral
- Detected
- Feb 3, 2026
- signal_type
sec-8k- signal_subtype
acquisitionCompleted
Use this data
Get every 8-K signal for Illumina and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Illumina this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/a44a56a6-aa59-48a4-bc96-af5a839de6d5 returns this record as JSON. POST /v1/companies/enrich returns every signal for illumina.com.
{
"signal_id": "a44a56a6-aa59-48a4-bc96-af5a839de6d5",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-02-03T13:18:31.341+00:00",
"company": {
"name": "Illumina",
"domain": "illumina.com"
},
"data": {
"detail": "Illumina has acquired SomaLogic and other entities for $350M cash plus up to $75M in milestones, signaling a major strategic expansion into proteomics. This triggers immediate post-merger integration challenges, including consolidating technologies, operations, and IT systems, creating budget and evaluation opportunities for integration and data management solutions.",
"metrics": {
"timeframe": "immediate",
"dollar_context": "Cash purchase price for Standard BioTools' proteomics business",
"dollar_millions": 350
},
"summary": "Illumina completes $350M cash acquisition of Standard BioTools' proteomics business",
"excerpts": "On January 30, 2026, the Company completed the Transaction.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1110803/000111080326000014/ilmn-20260130.htm",
"filing_date": "2026-01-30",
"filing_year": 2026,
"sales_relevance": "Active integration needs",
"signal_category": "strategic",
"regions_mentioned": [
"Singapore"
],
"technologies_mentioned": [
"proteomics"
]
}
}
curl https://signals.autobound.ai/v1/signals/a44a56a6-aa59-48a4-bc96-af5a839de6d5 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"illumina.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.